Federico Quaini

Adjunct Professor

University of Parma

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Federico Quaini is an Adjunct Professor at the University of Parma, Italy. His research focuses on immunotherapy in cancer treatment, including the role of biomarkers in metastatic renal cell carcinoma and the immune responses in advanced solid tumors. Additionally, he investigates the genetic and immune factors influencing tumor responses and has contributed to the field of bioengineering for cardiac tissue engineering.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (8)

Radim Kubeš

University Hospital in Motol

CZECH REPUBLIC

View details

Gian Matteo Rigolin

University of Ferrara

ITALY

View details

Antonio Cuneo

University of Ferrara

ITALY

View details

Mariateresa Giaimo

University of Parma

ITALY

View details

Gregorio Monica

University of Parma

ITALY

View details

Raffaella Zamponi

University of Parma

ITALY

View details

Ondrej Fiala

Charles University

CZECH REPUBLIC

View details

Giuseppe Luigi Banna

Honorary Associate Professor

University of Portsmouth

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Federico Quaini

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations

CAD204520 Targets <i>NOTCH1</i> PEST Domain Mutations in Lymphoproliferative Disorders.

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase

Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy

Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors

Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML

Editorial: Bioengineering of biomimetic microenvironments for cardiac tissue engineering

Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review

Collaborators (8)

Radim Kubeš

Gian Matteo Rigolin

Antonio Cuneo

Mariateresa Giaimo

Gregorio Monica

Raffaella Zamponi

Ondrej Fiala

Giuseppe Luigi Banna

Make your next move.